Sterling: Opening New Frontiers in Pharmaceutical Innovation
With nearly fifty years of experience in the manufacturing excellence of active pharmaceutical ingredients (APIs), Sterling has always been a solid, reliable, and internationally recognized partner. As we approach our 50th anniversary in 2026, we are entering a new strategic chapter that will expand our role within the pharmaceutical value chain.
Over the next 3–5 years, we are investing in new skills and technologies to move upstream in drug development — from pre-formulation to high-performance generic drug dossiers, and innovative solutions designed to improve therapeutic effectiveness and accessibility.
One of the pillars of this evolution is our focus on high-value pre-formulated products, with particular emphasis on nanoparticles for nasal delivery. This route is emerging as one of the most promising in systemic and local drug administration: bypassing first-pass metabolism, enabling rapid absorption, and in some cases, granting direct access to the central nervous system.
Nanoparticle platforms — polymeric, lipid-based, and hybrid — open the door to:
-
Improved bioavailability of poorly soluble molecules
-
Protection against enzymatic degradation
-
Controlled and targeted release
-
Extended residence time through enhanced mucosal adhesion
To seize this opportunity, we are building an interdisciplinary team dedicated to designing advanced pre-formulation platforms. Our goal is to support partners not only in developing high-performance generics, but also in repurposing existing drugs for new therapeutic applications.
This step is much more than an expansion: it is the natural evolution of our expertise, a bridge from strong chemical foundations to advanced pharmaceutical engineering.
With these initiatives, Sterling reaffirms its commitment to shaping a new generation of therapies that are more effective, safe, and accessible — for patients worldwide.
The future of Sterling has already begun. And it’s built on innovation, trust, and the will to contribute to global health.
With nearly fifty years of experience in the manufacturing excellence of active pharmaceutical ingredients (APIs), Sterling has always been a solid, reliable, and internationally recognized partner. As we approach our 50th anniversary in 2026, we are entering a new strategic chapter that will expand our role within the pharmaceutical value chain.
Over the next 3–5 years, we are investing in new skills and technologies to move upstream in drug development — from pre-formulation to high-performance generic drug dossiers, and innovative solutions designed to improve therapeutic effectiveness and accessibility.
One of the pillars of this evolution is our focus on high-value pre-formulated products, with particular emphasis on nanoparticles for nasal delivery. This route is emerging as one of the most promising in systemic and local drug administration: bypassing first-pass metabolism, enabling rapid absorption, and in some cases, granting direct access to the central nervous system.
Nanoparticle platforms — polymeric, lipid-based, and hybrid — open the door to:
-
Improved bioavailability of poorly soluble molecules
-
Protection against enzymatic degradation
-
Controlled and targeted release
-
Extended residence time through enhanced mucosal adhesion
To seize this opportunity, we are building an interdisciplinary team dedicated to designing advanced pre-formulation platforms. Our goal is to support partners not only in developing high-performance generics, but also in repurposing existing drugs for new therapeutic applications.
This step is much more than an expansion: it is the natural evolution of our expertise, a bridge from strong chemical foundations to advanced pharmaceutical engineering.
With these initiatives, Sterling reaffirms its commitment to shaping a new generation of therapies that are more effective, safe, and accessible — for patients worldwide.
The future of Sterling has already begun. And it’s built on innovation, trust, and the will to contribute to global health.